Healthcare Equipment and Supplies
Company Overview of Infraredx, Inc.
Infraredx, Inc. operates as a cardiovascular imaging company. The company engages in advancing the diagnosis and treatment of coronary artery diseases. The company’s products include dual-modality near-infrared spectroscopy intravascular ultrasound (IVUS) true vessel characterization imaging systems for identifying lipid core coronary plaques, and providing structural plaque information with IVUS; and optical catheters that provides a high resolution image of the structure of the plaque, as well as associated accessories. It serves hospital sites in the United States and Europe. The company was founded in 1998 and is headquartered in Burlington, Massachusetts.
34 Third Avenue
Burlington, MA 01803
Founded in 1998
Key Executives for Infraredx, Inc.
Founder, Chairman and Chief Medical Officer
Vice President of Operations Regulatory & Quality
Vice President of Global Sales
Vice President of Research & Development
Vice President of Marketing
Compensation as of Fiscal Year 2015.
Infraredx, Inc. Key Developments
InfraReDx Seeks Acquisitions
Dec 22 14
InfraReDx, Inc. has filed an IPO in the amount of $55 million. InfraReDx said, "We may use a portion of our net proceeds to acquire and invest in complementary products, technologies or businesses; however, we currently have no agreements or commitments to complete any such transaction and are not involved in negotiations to do so."
Infraredx Announces Research Collaboration with Massachusetts General Hospital to Explore New Generation of Cardiovascular Imaging Devices
Dec 16 14
Infraredx, Inc. announced a collaboration with Massachusetts General Hospital (MGH) and coronary imaging researcher, Gary Tearney, M.D., Ph.D., professor of pathology at Harvard Medical School, Mike and Sue Hazard Family MGH Research Scholar, and founder of the Tearney Lab at the Wellman Center for Photomedicine at MGH. The TVC Imaging System is the only FDA-cleared technology capable of rapidly, specifically and reliably identifying lipid core plaques, which are known to complicate stenting procedures and are suspected to be the vulnerable plaques that cause most heart attacks, using NIRS, and providing vessel structure information using intravascular ultrasound (IVUS). The multi-year collaboration will focus on research and development of new and combination technologies that aim to provide enhanced information about coronary disease in patients.
Infraredx Receives Regulatory Approval of TVC Imaging System in Japan
Sep 29 14
Infraredx, Inc. announced that its first-in-class, dual-modality intravascular imaging technology, TVC Imaging System(TM), and its TVC Insight(TM) Catheter received Shonin approval from the Japanese Ministry of Health, Labour and Welfare (MHLW). The TVC System makes it possible to determine the structure and chemical composition of the coronary plaques that complicate stenting, and are associated with heart attacks. The TVC Imaging System console and catheter will be exclusively distributed by Goodman, a subsidiary of Osaka-based Nipro Corporation, which has extensive experience commercializing IVUS and other imaging technologies in Japan. The TVC Imaging System integrates near-infrared spectroscopy (NIRS) to detect lipid-core plaques and enhanced intravascular ultrasound (IVUS) to visualize vessel structure, including the presence of plaques and the degree of stenosis (narrowing) due to plaque build-up. Lipid core plaque is a fatty coronary artery plaque associated with most heart attacks. The TVC Imaging System can identify plaques suspected to be vulnerable to rupture, which can cause a heart attack.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|